Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder

Ginsberg, Lawrence D.

doi:10.1017/s1092852900026353

Cited by 20Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder

Ginsberg, Lawrence D.·2009·CNS Spectrums

DOI 10.1017/s1092852900026353

Open this paper in CoChat — free account

Abstract

Despite significant progress in the development of antidepressant therapies, tolerability remains an important factor associated with the selection of appropriate antidepressant treatment. Side effects commonly reported by depressed patients taking antidepressants include weight gain, sexual dysfunction, and gastrointestinal effects. Tolerability issues associated with antidepressants can negatively impact treatment outcomes for patients with major depressive disorder. In addition, a drug's tolerability profile substantially influences a physician's choice of specific antidepressant therapy. Despite the availability of many antidepressants, empirical clinical evidence to guide physicians in making the best choice is limited and not always clear. Thus, it is key for clinicians to understand the short- and long-term outcomes and side effect profiles of the available antidepressants.

Integrity signals

Registry

Crossref · 10.1017/s1092852900026353

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Although sexual dysfunction has been reported with all classes of antidepressants, SSRIs are associated with higher rates.
“Although sexual dysfunction has been reported with all classes of AD (549), SSRIs are associated with higher rates (550-552).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [552]

Distributed Disturbances in Brain Structure and Function in Schizophrenia
Lewis, D. A. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 971 · see citing works
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · see citing works
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · see citing works
Effects of SSRIs on Sexual Function
Rosen, R. C., Lane, R. M., & Menza, M. A. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 649 · see citing works
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · see citing works
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.
(2000) · PubMed · Cited by 509 · see citing works
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 462 · see citing works
The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
Melfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1128 · Cited by 409 · see citing works
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · see citing works
Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: A Meta-Analysis of Original Data From 7 Randomized Controlled Trials
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304 · see citing works
Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder
D, M. F. M., Judge, R., HOOG, S. L., Nilsson, M., & Koke, S. C. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1109 · Cited by 266 · see citing works
Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for Depression: Patient Report Versus Physician Estimate
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235 · see citing works
Impaired Neuropsychological Performance in Euthymic Patients With Recurring Mood Disorders
Tham, A., Engelbrektson, K., Mathe, A. A., Johnson, L., Olsson, E., & Aberg-Wistedt, A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0105 · Cited by 229 · see citing works
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder
Lieberman, D. Z., Montgomery, S., Tourian, K. A., Brisard, C., Rosas, G. R., Padmanabhan, K., Germain, J., & Pitrosky, B. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32830263de · Cited by 214 · see citing works
Management of Patients With Treatment-Resistant Depression
Thase, M. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0308e08 · Cited by 158 · see citing works
Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder
Clayton, A. H., Kornstein, S. G., Prakash, A., Mallinckrodt, C. H., & Wohlreich, M. M. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00520.x · Cited by 151 · see citing works
Comparative Risk for Harms of Second-Generation Antidepressants: A Systematic Review and Meta-Analysis
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150 · see citing works
Which Factors Influence Psychiatrists’ Selection of Antidepressants?
Zimmerman, M. A., Posternak, M. A., Friedman, M. A., Attiullah, N., Baymiller, S., BOLAND, R. J., Berlowitz, S. L., Rahman, S., Uy, K. K., & Singer, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1285 · Cited by 139 · see citing works
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
Liebowitz, M. R., Manley, A. L., Padmanabhan, S. K., Ganguly, R., Tummala, R., & Tourian, K. A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802161923 · Cited by 134 · see citing works
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
Boyer, P., Montgomery, S., Lepola, U. M., Germain, J., Brisard, C., Ganguly, R., Padmanabhan, S. K., & Tourian, K. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32830cebed · Cited by 124 · see citing works
Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study
Behnke, K., Søgaard, J., Martin, S. D., Bäuml, J., Ravindran, A. V., Ågren, H., & Vester-Blokland, E. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085408.08426.05 · Cited by 115 · see citing works
Continuity Is the Main Challenge in Treating Major Depressive Disorder in Psychiatric Care
Melartin, T. K., Rytsälä, H. J., Leskelä, U. S., Lestelä-Mielonen, P. S., Sokero, T. P., & Isometsä, E. T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0210 · Cited by 111 · see citing works
Tolerability and safety of fluvoxamine and other antidepressants
Westenberg, H. G. M., & Sandner, C. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00865.x · Cited by 104 · see citing works
Randomized, Double-Blind Comparison of Venlafaxine and Sertraline in Outpatients With Major Depressive Disorder
Mehtonen, O. ‐., Søgaard, J., Roponen, P., Behnke, K., & Venlafaxine 631 Study Group (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0204 · Cited by 97 · see citing works
Safety and tolerability of the new antidepressants.
Nelson, J. C. (1997) · PubMed · Cited by 76 · see citing works
Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients
Versiani, M., Moreno, R. A., van Moorsel, C. J. A., Schutte, A. J., & Study, C. E. O. A. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00004 · Cited by 76 · see citing works
A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive Disorder
Liebowitz, M. R., & Yeung, P. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1105 · Cited by 73 · see citing works
Reboxetine: a review of antidepressant tolerability.
Mucci, M. (1997) · PubMed · Cited by 70 · see citing works
Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60 · see citing works
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care
Wade, A. G., Crawford, G. M., Angus, M., Wilson, R., & Hamilton, L. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000068045.82050.00 · Cited by 58 · see citing works
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder
Pigott, T. A., Prakash, A., Arnold, L. M., Aaronson, S. T., Mallinckrodt, C. H., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188107 · Cited by 58 · see citing works
Effects of the Antidepressant Duloxetine on Body Weight
Wise, T. N., David, P., Pangallo, B. A., Losin, W. G., & Wiltse, C. G. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0503 · Cited by 48 · see citing works
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dünner, D. L., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.040 · Cited by 46 · see citing works
The Safety and Tolerability of Duloxetine Compared With Paroxetine and Placebo
Nelson, J. C., Pritchett, Y., Martynov, O., Yu, J., Mallinckrodt, C. H., & Detke, M. J. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0404 · Cited by 44 · see citing works

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
Jacobsen, P. L., Mahableshwarkar, A. R., Serenko, M., Chan, S., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09335 · Cited by 116 · see citing works
Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention
Nollet, M., & Leman, S. (2013) · CNS Drugs · doi:10.1007/s40263-013-0064-z · Cited by 89 · see citing works
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder
Alam, M. Y., Jacobsen, P. L., Chen, Y., Serenko, M., & Mahableshwarkar, A. R. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000010 · Cited by 75 · see citing works
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
Dodd, S., Mitchell, P. B., Bauer, M., Yatham, L. N., Young, A. H., Kennedy, S. H., Williams, L. J., Suppes, T. M., López‐Jaramillo, C., Trivedi, M. H., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1379609 · Cited by 66 · see citing works
α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties
Mineur, Y. S., Einstein, E. B., Seymour, P. A., Coe, J. W., O'Neill, B. T., Rollema, H., & Picciotto, M. R. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328347546d · Cited by 49 · see citing works
Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45 · see citing works
A Review of Antidepressant Therapy in Primary Care
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 40 · see citing works
Expression of the 5-HT1A Serotonin Receptor in the Hippocampus Is Required for Social Stress Resilience and the Antidepressant-Like Effects Induced by the Nicotinic Partial Agonist Cytisine
Mineur, Y. S., Einstein, E. B., Bentham, M. P., Wigestrand, M. B., Blakeman, S., Newbold, S. A., & Picciotto, M. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.269 · Cited by 33 · see citing works
Concomitant Psychotropic Medication Use During Treatment of Schizophrenia Patients: Longitudinal Results from the CATIE Study
Chakos, M., Patel, J., Rosenheck, R. A., Glick, I. D., Hamner, M. B., Miller, D. D., Tapp, A. M., & Miller, A. L. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.3.2 · Cited by 22 · see citing works
Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing
Misri, S. K., Swift, E., Abizadeh, J., & Shankar, R. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316656297 · Cited by 17 · see citing works
Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults
Matsuno, K., Nakamura, K., Aritomi, Y., & Nishimura, A. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.381 · Cited by 16 · see citing works
Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials
Meshkat, S., Kwan, A. T. H., Le, G. H., Wong, S., Teopiz, K. M., Wang, L., Rosenblat, J. D., Rhee, T. G., Cao, B., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.008 · Cited by 15 · see citing works
Clinical preference for factors in treatment of geriatric depression
Riepe, M. W. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75450 · Cited by 6 · see citing works
The Impact of Antidepressant-Associated Sexual Dysfunction on Treatment Adherence in Patients with Major Depressive Disorder
Clayton, A. H. (2013) · Current Psychiatry Reviews · doi:10.2174/15734005113096660007 · Cited by 6 · see citing works
Anti-inflammatory effects of Gualou Guizhi decoction in transient focal cerebral ischemic brains. [Corrected].
Hu, H.-X., Lin, R.-H., Zhu, X.-Q., Li, Z., & Chen, L.-D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3511 · Cited by 4 · see citing works
The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
Ma, D., Li, G., & Wang, X. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s103173 · Cited by 5 · see citing works
Retracted Article: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study
Wang, J., Liu, X., Feng, C., Quan, B., & Fu, H.-R. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1397700 · Cited by 5 · see citing works
Retracted
QSAR-Guided Design of Serotonin Transporter Inhibitors Supported by Molecular Docking and Biased Molecular Dynamics
Veselinović, A. M., Culletta, G., Živković, J. V., Sunaric, S. M., Mitić, Ž. J., Roomi, M. S., & Tutone, M. (2026) · Pharmaceuticals · doi:10.3390/ph19030444 · Cited by 1 · see citing works
World Psychiatryis indexed in PubMed, Current Contents/Clinical Medicine, Current Contents/Social and Behavioral Sciences, Science Citation Index, and EMBASE Âñåìèðíàÿ Ïñèõèàòðè÷åñêàÿ Àññîöèàöèÿ (ÂÏÀ)
Maj, M., Ïðåçèäåíò, È., Tasman, A., & Herrman, H. (2011)

Safety and tolerability of antidepressants: weighing the impact on treatment decisions.
Schatzberg, A. F. (2007) · PubMed · Cited by 43 · see citing works
The Efficacy, Tolerability, and Safety of Contemporary Antidepressants
Papakostas, G. I. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.03gry · Cited by 65 · see citing works
Tolerability issues during long-term treatment with antidepressants
Cassano, P., & Fava, M. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490281618 · Cited by 154 · see citing works
Management of Patients With Treatment-Resistant Depression
Thase, M. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0308e08 · Cited by 158 · see citing works
Factors Impacting the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder at Risk for Nonadherence
Shelton, C. I. (2009) · CNS Spectrums · doi:10.1017/s1092852900026365 · Cited by 9 · see citing works

Authors: Ginsberg, L. D.
Corresponding author: Ginsberg, Lawrence D.
Venue: CNS Spectrums
Publisher: Cambridge University Press (CUP)
Published: 2009
Volume: 14
Issue: S12
Pages: 8-14
ISSN: 1092-8529 (ISSN-L)
2165-6509
DOI: 10.1017/s1092852900026353
OpenAlex: W2408397345
Cited by: 19
References: 35
Citations by year: 2026: 1 · 2024: 1 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 1
FWCI: 0.96
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 2136 d)
Locations: CNS Spectrums (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: antidepressant tolerability, major depressive disorder, antidepressant selection, antidepressant side effects, weight gain, sexual dysfunction, gastrointestinal effects, treatment outcomes
MeSH terms: Adult, Antidepressive Agents, Choice Behavior, Major Depressive Disorder, Drug Tolerance, Female, Gastrointestinal Diseases, Humans, Quality of Life, Sexual Dysfunction, Physiological, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks